Updates in Mold-Related Illness

---

Release Date: 9/10/2025 
Expiration Date: 12/31/2026 

---

Activity Overview
This advanced activity provides clinicians with updated insights into mast cell involvement, precision mycotoxin mechanisms, and evolving diagnostic strategies for mold-related illness. Participants will learn to recognize symptom patterns, optimize laboratory testing, and apply targeted treatment approaches. The course emphasizes patient safety through protective measures that support the microbiome, detoxification systems, and affected tissues prior to antifungal therapies when indicated.

---

Target Audience
This activity is designed for an audience of physicians, nurses, psychologists, and other healthcare professionals interested in applying advanced, evidence-informed strategies for the diagnosis and treatment of mold-related illness.

---

Learning Objectives

Mast Cell Impacts of Mold Spores and Spore Fragments
Upon completion of the educational activity, participants should be able to:

• Describe the effects of toxic indoor mold exposure on mast cell function and immune regulation.
• Explain how mast cell activation contributes to heightened sensitivities and multi-system symptoms in affected patients.

Mold Mycotoxins and Specific Mechanisms
Upon completion of the educational activity, participants should be able to:

• Explain the unique mechanisms of action for mycotoxins associated with water-damaged building exposure.
• Differentiate between shared and distinct health impacts of individual mycotoxins.
• Analyze specific mycotoxin mechanisms in relation to variations in patient symptom presentation.

Mycotoxin Assessment
Upon completion of the educational activity, participants should be able to:

• Identify symptom patterns consistent with specific mycotoxin injury.
• Apply appropriate laboratory preparation and testing combinations to improve detection accuracy.
• Discuss limitations of existing laboratory methods and factors that may influence results.

Treatment of Mold and Mycotoxins
Upon completion of the educational activity, participants should be able to:

• Select detoxification strategies aligned with the known excretion pathways of individual mycotoxins.
• Evaluate pharmaceutical treatment options for clinically significant toxic indoor mold exposure.
• Incorporate protective measures for the microbiome, detoxification organs, and affected tissues prior to initiating antifungal therapies.

---

Criteria for Success
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate.  You must participate in the entire activity to receive credit. If you have questions about this activity, please contact AKH Inc. at lritley@akhcme.com.

---

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Credit being awarded: 3.0 ANCC contact hours

Psychologists

---

Commercial Support
There is no commercial support for this activity.

---

DISCLOSURES
Name	Relationship	Commercial Interest
Jill Crista, ND	N/A	Nothing to disclose
Dorothy Caputo, MA, BSN, RN – President, AKH Inc., Advancing Knowledge in Healthcare	N/A	Nothing to disclose
Jennifer Kasey, Psy.D.	N/A	Nothing to disclose
Michele Bielarski, RN (planner/reviewer)	N/A	Nothing to disclose
AKH Inc Staff and Planners	N/A	Nothing to disclose
Crista Corporation Staff and Planners	N/A	Nothing to disclose
All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product 
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

---

Disclaimer 
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with “Opt Out” in the subject line.

---